Free Trial

Fortrea (FTRE) Competitors

Fortrea logo
$7.82 +0.52 (+7.05%)
As of 10:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FTRE vs. VCYT, ADUS, PGNY, CELC, ARDT, LFST, PACS, NHC, VRDN, and AVAH

Should you be buying Fortrea stock or one of its competitors? The main competitors of Fortrea include Veracyte (VCYT), Addus HomeCare (ADUS), Progyny (PGNY), Celcuity (CELC), Ardent Health (ARDT), LifeStance Health Group (LFST), PACS Group (PACS), National HealthCare (NHC), Viridian Therapeutics (VRDN), and Aveanna Healthcare (AVAH). These companies are all part of the "healthcare" industry.

Fortrea vs. Its Competitors

Veracyte (NASDAQ:VCYT) and Fortrea (NASDAQ:FTRE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Fortrea had 14 more articles in the media than Veracyte. MarketBeat recorded 29 mentions for Fortrea and 15 mentions for Veracyte. Fortrea's average media sentiment score of 0.84 beat Veracyte's score of 0.69 indicating that Fortrea is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
3 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fortrea
8 Very Positive mention(s)
3 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Veracyte presently has a consensus target price of $40.90, indicating a potential upside of 39.79%. Fortrea has a consensus target price of $13.30, indicating a potential upside of 69.88%. Given Fortrea's higher probable upside, analysts clearly believe Fortrea is more favorable than Veracyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
Fortrea
1 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.15

Veracyte has a net margin of 5.50% compared to Fortrea's net margin of -37.57%. Veracyte's return on equity of 6.07% beat Fortrea's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte5.50% 6.07% 5.53%
Fortrea -37.57%5.25%1.72%

Veracyte has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, Fortrea has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Veracyte has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$479.13M4.80$24.14M$0.3388.66
Fortrea$2.73B0.26-$328.50M-$11.38-0.69

Summary

Veracyte beats Fortrea on 10 of the 15 factors compared between the two stocks.

Get Fortrea News Delivered to You Automatically

Sign up to receive the latest news and ratings for FTRE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FTRE vs. The Competition

MetricFortreaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$710.87M$3.07B$5.58B$9.86B
Dividend YieldN/A2.29%4.64%4.14%
P/E Ratio-0.6920.5230.5525.47
Price / Sales0.26358.77457.79104.67
Price / Cash4.0740.7837.7258.50
Price / Book1.217.698.466.04
Net Income-$328.50M-$54.75M$3.26B$265.10M
7 Day Performance18.98%2.83%2.59%2.11%
1 Month Performance53.21%10.99%5.07%3.27%
1 Year Performance-64.77%13.01%42.40%25.63%

Fortrea Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FTRE
Fortrea
3.6912 of 5 stars
$7.83
+7.1%
$13.30
+69.9%
-63.5%$710.87M$2.73B-0.6915,500Earnings Report
Insider Trade
Analyst Revision
Gap Down
VCYT
Veracyte
2.6677 of 5 stars
$27.99
+2.3%
$40.90
+46.1%
-3.8%$2.15B$445.76M84.82790
ADUS
Addus HomeCare
4.9156 of 5 stars
$111.95
+1.6%
$142.86
+27.6%
-9.9%$2.03B$1.15B24.7149,703Analyst Revision
PGNY
Progyny
1.737 of 5 stars
$21.75
-4.8%
$24.90
+14.5%
+3.6%$1.96B$1.17B36.86310Earnings Report
CELC
Celcuity
0.8446 of 5 stars
$46.66
+1.7%
$39.20
-16.0%
+232.4%$1.79BN/A-15.4040Upcoming Earnings
ARDT
Ardent Health
3.9639 of 5 stars
$12.04
+1.3%
$19.55
+62.4%
-22.7%$1.70B$5.97B6.6524,900Analyst Forecast
Analyst Revision
LFST
LifeStance Health Group
3.0635 of 5 stars
$4.57
+4.6%
$8.50
+86.0%
-15.3%$1.70B$1.25B-91.4010,218Earnings Report
PACS
PACS Group
3.104 of 5 stars
$11.35
+1.9%
$34.29
+202.0%
-65.4%$1.70B$3.11B0.0032,433
NHC
National HealthCare
N/A$103.43
+3.0%
N/A-14.1%$1.60B$1.37B12.9612,400Dividend Announcement
VRDN
Viridian Therapeutics
1.644 of 5 stars
$16.89
+2.9%
$37.00
+119.1%
+17.5%$1.34B$300K-4.4150Trending News
Earnings Report
Analyst Revision
AVAH
Aveanna Healthcare
1.1627 of 5 stars
$6.83
+11.2%
$6.10
-10.7%
+56.0%$1.28B$2.02B85.3833,500News Coverage
Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:FTRE) was last updated on 8/13/2025 by MarketBeat.com Staff
From Our Partners